FOR IMMEDIATE RELEASE May 3, 2023 Media Contact: Cole Archer Director of Marketing & Communications Communication@LissMD.com (706) 327-4000   Eli Lilly and Company (NYSE: LLY) have announced that Alzheimer’s drug, donanemab, showed the ability to significantly slow cognitive decline in those with early symptomatic Alzheimer’s disease. Eli Lilly stated that they plan to file for FDA approval on this drug by the end of June.  Columbus, Georgia, home to Columbus Memory Center, once again played a substantial role in this drug’s journey to success. COLUMBUS, GA. May 3rd, 2023 – [...]